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Abstract 
 
Purpose: The primary objective of this study was to estimate the prevalence of vaccination and 
HBV infection status of adults and to evaluate the trend in self reported vaccination and 
seroprevalence for Hepatitis B for this population.  Additionally, this study sought to assess the 
association between vaccination rates, seroprevalence (HBsAg, anti-HBc, and anti-HBs), 
demographic (age, gender, location of birth, race/ethnicity), and socioeconomic (annual 
household income, education level, insurance coverage and access to care, marital status) 
characteristics.   
 
Methods: Eight years, 1999-2006, of the National Health and Nutrition Examination Survey 
(NHANES) data were used. NHANES participants aged 20-59 years who contributed data via 
the household interview and laboratory component were eligible for this study. Two sources of 
vaccination status were available.  The vaccination status was identified through self-report. 
Those who answered yes to “less than three doses” and “at least three doses” were classified as 
vaccinated.  Vaccination status was also verified through serologic markers. All analyses were 
weighted to consider the complex weighting scheme and adjusted to the 2000 US census 
population.  Vaccination rates were calculated for both low and high risk populations. 95% 
confidence intervals (95% CI) of each estimate were also calculated.  The association between 
potential predictors of vaccination (demographic variables, socioeconomic status, high risk, and 
health care access and utilization variables) and vaccination status was assessed using bivariate 
analysis.  We used logistic regression model to obtain odds ratios and their 95% confidence 
intervals for the association between predictor variables and vaccination status after adjusting for 
all potential confounding factors. 
 
Results: Vaccinated adults were more likely to be female, younger (20-29), Non-Hispanic white, 
married, born in the United States, have some education beyond high school, have a household 
income greater than $20000, health insurance coverage, a source of usual medical care, report a 
health status of good or higher, be non-smokers, and have no history of alcohol abuse.  High risk 
adults comprised about 16% of adults who had received at least one dose of the Hepatitis B 
vaccine. Unvaccinated adults were more likely to be male, over the age of 40, Non-Hispanic 
white, born in the United States, married, have some education beyond high school, have a 
household income greater than $20,000, live in a household of 6 or fewer people, have health 
insurance coverage, and a source of usual care. When comparing the self reported vaccination 
status with serologic status, almost half of the adults who reported receiving all three doses of the 
vaccine tested negative for immunity. For all adults the prevalence increased from 23.4% to 
39.1%.  Compared to adults in 1999-2000, adults were twice as likely to report vaccination in 
2005-2006 (OR=2.1 95% CI [1.77, 2.49]). 
 
Conclusions: Although, hepatitis B vaccination rates are rising, only 32% of high risk adults are 
vaccinated.  The rise in vaccination rates in young adults is mostly related to childhood 
immunization strategies and not strategies aimed at adults.  Older males, those with less than 
high school education, without health insurance coverage and a source of usual care were least 
likely to be vaccinated.  More targeted interventions are needed to educate and vaccinate the 
adult population and to create a means for identifying those at risk and those already vaccinated. 
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Determinants of Hepatitis B Vaccination among Adults in the United States: NHANES 
1999-2006 
Conschetta R. Wright 
INTRODUCTION 
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus 
(HBV) and a major global health problem. An estimated two billion people globally have been 
infected with HBV, and more than 350 million have chronic liver infections.1 In the United 
States, there are approximately 1.3 million people living with chronic HBV.2 During 2006, a 
total of 4,713 acute, symptomatic cases of hepatitis B were reported.2 While the overall 
incidence has declined 81% since 1990, asymptomatic infections and underreporting accounted 
for an estimated 46,000 new infections in 2006. HBV puts chronic carriers at high risk of death 
from cirrhosis and hepatocellular carcinoma.  
HBV is transmitted by percutaneous or mucosal exposure to the blood or body fluids of 
an infected person.2 This occurs most often through intravenous drug use (IDU), sexual contact, 
or contact from an infected mother to her infant during delivery. HBV can also be transmitted 
through nonsexual interpersonal contact over an extended period.  For example, household 
contacts of a person with chronic HBV infection are at higher risk of contracting the virus.2   
The two primary sources of HBV infection for infants and children are perinatal 
transmission from infected mothers and horizontal transmission from contact with infected 
household members.3 Adolescents are at risk for HBV infection primarily through high-risk 
sexual activity and injection-drug use. Among adults, HBV transmission occurs principally 
among unvaccinated adults with risk behaviors for HBV transmission (e.g., heterosexuals with 
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multiple sex partners, injection-drug users [IDUs], and men who have sex with men [MSM]) and 
horizontal transmission.   
No treatment is currently recommended for acute hepatitis B.4 Supportive care is the 
primary therapy. Those with chronic HBV infection require regular medical evaluation and 
monitoring to determine if the disease is progressing and to identify liver damage or 
hepatocelluar carcinoma. For chronic infection, several antiviral drugs are available.  However, 
because of expense and possible needs for hospitalization, prevention has emerged as a more 
practical approach.   
The current form of the hepatitis B vaccine has been used in the United States since 
1986.9 Before 1991, the vaccine was recommended only for people who were identified to be at 
a high risk for acquiring the infection. Adults at increased risk for infection include health care 
workers, dialysis patients, household contacts and sex partners of persons with chronic HBV 
infection, recipients of certain blood products, persons with a recent history of multiple sex 
partners or an STD, MSM, and injection-drug users.2 Despite these recommendations, coverage 
remained low among adults at risk for HBV infection remained low.5,6 In 1991, 
recommendations for vaccination of unvaccinated adults at high risk for HBV infection became 
part of the national strategy adopted by Advisory Committee on Immunization Practices (ACIP) 
to eliminate HBV transmission in the United States.9  Immunization strategies for infants, 
children, and adolescents have been successful.3,6  Hepatitis B vaccine has been integrated into 
the childhood vaccination schedule, and infant vaccination coverage levels now are comparable 
to those of other childhood vaccines.6 
For adults, ongoing HBV transmission occurs primarily among unvaccinated adults with 
risk behaviors for HBV transmission. While studies have shown a slight increase in vaccination 
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coverage among this population between 2000 and 2004, it is attributed to the 35% decline in 
acute hepatitis B incidence that occurred during this period.7 Incidence of acute hepatitis B 
remains highest among adults, who accounted for approximately 95% of an estimated 51,000 
new HBV infections in 2005.3 Acceptance of vaccination is high among adults who are offered 
vaccination.  The low adult vaccination coverage reflects the lack of hepatitis B vaccination 
services and missed vaccination opportunities in settings in which a large proportion of adults at 
risk for HBV infection. 8  
OBJECTIVES 
Hepatitis B incidence among adults is expected to decline during the next decade as 
cohorts of those vaccinated in infancy, childhood, and adolescence reach adulthood.9 However, 
new implementation strategies are needed to protect unvaccinated adults at risk for HBV 
infection. In order to meet Healthy People 2010 objectives related to Hepatitis B vaccination 
among adults with high risk behaviors, an analysis of the factors that affect vaccination rates 
should be completed. The primary objective of this study was to estimate the prevalence of 
vaccination and HBV infection status of adults and to evaluate the trend in self reported 
vaccination and seroprevalence for Hepatitis B for this population.  Additionally, this study 
sought to assess the association between vaccination rates, seroprevalence (HBsAg, anti-HBc, 
and anti-HBs), demographic (age, gender, location of birth, race/ethnicity), and socioeconomic 
(annual household income, education level, insurance coverage and access to care, marital status) 
characteristics.   
METHODS 
Eight years, 1999-2006, of the National Health and Nutrition Examination Survey 
(NHANES) data were used. The National Center for Health Statistics (NCHS), Division of 
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Health Examination Statistics (DHES), part of the Centers for Disease Control and Prevention 
(CDC), conducts the surveys.  NHANES is a program of studies designed to assess the health 
and nutritional status of adults and children in the United States. The survey is unique in that it 
combines interviews and physical examinations. The NHANES interview includes demographic, 
socioeconomic, dietary, and health-related questions. The examination component consists of 
medical, dental, physiological measurements, and laboratory tests administered by highly trained 
medical personnel.  
The NHANES survey design is a stratified, multistage probability sample that is 
weighted to represent the civilian non-institutionalized U.S. population.10-13 The sample for the 
survey is selected to represent the U.S. population of all ages. To produce reliable statistics, 
NHANES over-samples of low-income persons, adolescents 12–19 years, persons 60+ years of 
age, African Americans, and Mexican Americans.14-17  
Study population 
NHANES participants aged 20-59 years who contributed data via the household 
interview and laboratory component were eligible for this study.  Participants in this age range 
were asked questions related to sexual practices and illegal drug use.  Participants were not 
included in this study if they had missing data related to immunization status, sexual behavior, 
drug use, and HBV serology data.  The final analytic sample consisted of 7273 participants 
representing 99,263,120 Americans.  The unweighted sample sizes of adults analyzed were 1431 
for 1999-2000, 2037 for 2001-2002, 1856 for 2003-2004, and 1949 for 2005-2006.   
Laboratory analysis 
Blood specimens were processed, stored, and shipped to the Division of Viral Hepatitis, 
National Center for Infectious Diseases, National Centers for Disease Control and Prevention. 
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Details on the serologic methods used by NHANES are discussed extensively elsewhere.18-21 
Briefly, the Hepatitis B core antibody (anti-HBc) Ortho HBc ELISA Test System detects prior 
exposure. The Hepatitis B surface antigen (HBsAg) AUSZYME Monoclonal test is a solid-phase 
“sandwich” enzyme immunoassay is used to detect current infection with HBV. The Hepatitis B 
surface antibody (anti-HBs) test used the AUSAB EIA which detects exposure to the antigen or 
vaccine.   
Hepatitis C virus (anti-HCV) was measured using direct solid-phase enzyme 
immunoassay with the anti-HCV screening ELISA. For HIV status, specimens were tested using 
the Synthetic Peptide Enzyme Immunoassay (EIA) (Genetic Systems HIV-1/HIV-2 Peptide EIA) 
for the detection of antibody to human immunodeficiency virus type 1 or type 2 (HIV-1 and 
HIV-2) or both (Bio-Rad Laboratories, Hercules, CA). Blood and urine specimens were 
processed, stored, and shipped to the Division of AIDS, STD, and TB, National Center for HIV, 
STD, and TB Prevention, National Centers for Disease Control and Prevention.18-21  
Determinants 
The Advisory Committee on Immunization Practices (ACIP) recommends routine pre-
exposure vaccination for populations at higher risk for HBV as described in Table 1.22  The 
NHANES data used in this study is capable of capturing the majority of high-risk groups related 
to sexual practice (more than one sexual partner within 30 days prior to the interview,  
MSM/homosexual or bisexual men), illegal drug use (ever used intravenous drugs), recent 
history of sexually transmitted infections (genital herpes, genital warts, gonorrhea, chlamydia, 
HIV, and chronic liver disease (Hepatitis C).  Since questions regarding sexual orientation were 
not asked until 2001, males who responded homosexual or bisexual were coded as high risk in 
addition to answers provided for lifetime sexual history with males. Participants were 
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categorized as higher risk of HBV if they met at least one of these definitions through self-report 
or laboratory data (HCV, HIV).  Participants who did not meet the criteria for higher risk were 
categorized as being lower risk for contracting HBV.   
Table 1. Individuals classified as being at higher risk for HBV22 
• Susceptible sex partners of hepatitis B surface antigen (HBsAg)-positive persons  
• Sexually active persons who are not in a long-term, mutually monogamous 
relationship (e.g., >1 sex partner during the previous 6 months)  
• Persons seeking evaluation or treatment for a sexually transmitted disease  
• Men who have sex with men  
• Injection drug users  
• Susceptible household contacts of HBsAg-positive persons  
• Healthcare and public safety workers at risk for exposure to blood or blood-
contaminated body fluids  
• Persons with end-stage renal disease, including predialysis, hemodialysis, peritoneal 
dialysis, and home dialysis patients  
• Residents and staff of facilities for developmentally disabled persons  
• Travelers to regions with intermediate or high rates of endemic HBV infection  
• Persons with chronic liver disease  
• Persons with HIV infection  
• All other persons seeking protection from HBV infection — acknowledgment of a 
specific risk factor is not a requirement for vaccination 
Note: Boldface indicate which risk factors are captured by NHANES 
Outcome variable 
Two sources of vaccination status were available.  The vaccination status was identified 
through self-report to the question “Have you ever received the 3-dose series of the hepatitis B 
vaccine?”.14-17 The questionnaire provided a description of the vaccine.  Those who answered 
yes to “less than three doses” and “at least three doses” were classified as vaccinated.  
Vaccination status was also verified through serologic markers. Table 2 provides interpretations 
for hepatitis B serologic markers. Blood specimens were analyzed for HBsAg, anti-HBc, and 
anti-HBs.  Serologic status was classified as vaccinated (immune due to Hepatitis B vaccination), 
unvaccinated (susceptible), and history of Hepatitis B infection (immune due to natural 
infection). Since NHANES does not test for the presence of IgM antibody to hepatitis B core 
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antigen (IgM anti-HBc), it is not possible to determine if participants are acutely or chronically 
infected.   
Table 2. Interpretation of hepatitis B serologic test results23 
Tests Results Interpretation 
HBsAg 
anti-HBc 
anti-HBs  
negative 
negative 
negative 
Susceptible or loss of anti-HBs over time after 
vaccinated 
HBsAg 
anti-HBc 
anti-HBs  
negative 
positive 
positive 
Immune due to natural infection 
HBsAg 
anti-HBc 
anti-HBs  
negative 
negative 
positive 
Immune due to hepatitis B vaccination 
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs  
positive 
positive 
positive 
negative 
Acutely infected  
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs  
positive 
positive 
negative 
negative 
Chronically infected 
HBsAg 
anti-HBc 
anti-HBs  
negative 
positive 
negative 
Interpretation unclear; four possibilities: 
1. Resolved infection (most common) 
2. False-positive anti-HBc, thus susceptible  
3. "Low level" chronic infection 
4. Resolving acute infection 
 
Potential confounders 
Based on our literature review1-9,, we evaluated the following variables for confounding: 
age, gender, race/ethnicity, location of birth, education level, marital status, age at first 
intercourse, sexual orientation, household size, annual household income, insurance status, 
health care access, health status, history of alcohol abuse, and current tobacco use.  Age was 
categorized as 20-29, 30-39, 40-49, and 50-59. Race/ethnicity was coded as non-Hispanic white, 
non-Hispanic black, Hispanic, and other. Location of birth was categorized as US-born, Mexico-
born, and other.  Education level was classified as less than high school, completed high school, 
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and more than high school. Marital status was classified as never married, married, previously 
married, and living with partner.  
Household size was grouped as 1-3 people, 4-6 people, and 7 or more people.  For health 
care access, participants were asked if they had a source of usual care.  Self-reported health 
status was categorized as excellent, very good, good, fair, and poor. The following variables 
were dichotomized: age at first intercourse (less than 18 years old, 18 years and older), insurance 
status (current coverage, no coverage), history of alcohol abuse (yes, no), and cigarette use 
(smoker, non-smoker).  Participants were classified as having a history of alcohol abuse if they 
answered yes to the question “Was there ever a time or times in your life when you drank 5 or 
more drinks of any kind of alcoholic beverage almost every day?”.14-17 
Statistical analysis 
 All analyses were weighted to consider the complex weighting scheme and adjusted to 
the 2000 US census population.  Vaccination rates were calculated for both low and high risk 
populations. 95% confidence intervals (95% CI) of each estimate were also calculated.  The 
association between potential predictors of vaccination (demographic variables, socioeconomic 
status, high risk, and health care access and utilization variables) and vaccination status was 
assessed using bivariate analysis.  We used logistic regression model to obtain odds ratios and 
their 95% confidence intervals for the association between predictor variables and vaccination 
status after adjusting for all potential confounding factors.  SAS version 9.2 was used to produce 
the appropriate estimates and standard errors. 
RESULTS 
Table 3 compares the demographics, socioeconomic status, and health care access and 
utilization, and risk variables with vaccination status for all adults.  Vaccinated adults were more 
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likely to be female, younger (20-29), Non-Hispanic white, married, born in the United States, 
have some education beyond high school, have a household income greater than $20000, health 
insurance coverage, a source of usual medical care, report a health status of good or higher, be 
non-smokers, and have no history of alcohol abuse.  High risk adults comprised about 16% of 
adults who had received at least one dose of the Hepatitis B vaccine. 
Unvaccinated adults were more likely to be male, over the age of 40, Non-Hispanic 
white, born in the United States, married, have some education beyond high school, have a 
household income greater than $20,000, live in a household of 6 or fewer people, have health 
insurance coverage, and a source of usual care.  Similar to the vaccinated group, they rated their 
health status as good or higher, they were non-smokers, and had no history of alcohol abuse. 
Similar to the vaccinated group, high risk adults were about 15% of unvaccinated adults.   
Table 3.  Comparison of adults vaccinated and unvaccinated for hepatitis B virus: 
NHANES 1999-2006 
  Vaccinated Unvaccinated 
  % %  
Variables     
Sample (n) 
  
  Unweighted 2220 5053 
  Weighted 30276510 68986610 
Gender   
     Male 41.90 53.79 
     Female 58.10 46.21 
Age   
     20-29 32.10 15.95 
     30-39 27.80 25.45 
     40-49 25.13 32.26 
     50-59 14.97 26.34 
Race/ethnicity   
Non-Hispanic White 73.22 75.86 
Non-Hispanic Black 10.66 8.66 
Hispanic 11.25 12.03 
Other 4.87 3.45 
14 
 
Table 3.  Comparison of adults vaccinated and unvaccinated for hepatitis B virus: 
NHANES 1999-2006 (continued) 
  Vaccinated Unvaccinated 
  % %  
Variables     
Country of birth   
US 88.96 87.86 
Mexico 2.76 4.46 
Abroad 8.28 7.68 
Marital status   
Never married 23.40 14.55 
Married 55.06 62.44 
Previously married 12.94 15.07 
Living with partner 8.60 7.93 
Age at first intercourse   
     Less than 18 years old 60.02 57.86 
     >=18 years old 39.98 42.14 
Education   
Less than high school 10.02 15.04 
Completed high school 19.49 27.45 
Some college or beyond 70.49 57.51 
Income   
   Less than $20,000 14.03 13.45 
   $20,000 or more 85.97 86.55 
Household size   
1-3 people 59.94 63.43 
4-6 people 37.14 33.68 
7 or more people 2.92 2.89 
Current health insurance 
coverage 
  
     Yes 82.25 79.72 
     No 17.75 20.28 
Source of usual care   
     Yes 86.18 82.54 
     No 13.82 17.46 
Health status   
     Excellent 24.44 22.51 
     Very good 35.13 32.99 
     Good 28.81 30.66 
     Fair 9.87 11.09 
     Poor 1.75 2.75 
Cigarette smoker   
     Smoker 29.53 29.93 
     Non-smoker 70.47 70.07 
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Table 3.  Comparison of adults vaccinated and unvaccinated for hepatitis B virus: 
NHANES 1999-2006 (continued) 
  Vaccinated Unvaccinated 
  % %  
Variables     
History of alcohol abuse   
     Yes 13.91 17.93 
     No 86.09 82.07 
Received at least 1 dose Hepatitis 
B vaccine     
     High risk 16.02 14.65 
     Low risk 83.98 85.35 
 
Table 4 shows what factors affect the likelihood of adults receiving at least one dose of 
the Hepatitis B vaccine along with crude and adjusted ORs and their 95% CIs.  The crude 
analysis indicates that those who were vaccinated were more likely to be female, under the age 
of 50, of a minority ethnicity/race, never married, born in the United States,  have education 
beyond high school, live in a household of 4-6 people, have current health insurance coverage, 
and rate their health status as excellent. The adjusted model shows that males are almost 40% 
less likely to be vaccinated compared to females (OR=0.64, 95% CI [0.57, 0.73]).  Adults aged 
50-59 were least likely to be vaccinated.  Vaccination odds increased with every decrease in 
decade with 20-29 year olds three times more likely to be vaccinated (OR=3.69 95% CI [2.98, 
4.56]). Minorities vaccination odds were only significant for Non-Hispanic blacks (OR=1.22 
95% CI [1.03, 1.43]) and other minorities (OR=1.40 95% CI [1.06, 1.83]).  Adults who had 
never been married were vaccinated 25% more often than married adults (OR=1.25 95% CI 
[1.04, 1.50]).  Having less than some college education, decreased the odds of vaccination by 
half (ORless than HS=0.51 95% CI [0.41, 0.64]).  Vaccination status increased by 20% with 
household size, but only those who lived in a household of 4-6 people was found to be 
statistically significant (OR=1.24 95% CI [1.08,1.44]) .  Factors that had little or no impact on 
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vaccination status included country of birth, income, self reported health status, being a smoker, 
or having a history of alcohol abuse.   
Table 4. Factors associated with receipt of hepatitis B vaccination among adults:  
NHANES 1999-2006 
  Vaccinated Unvaccinated Odds Ratios 
  % % Crude (95% CI) Adjusted (95% CI) 
Variables       
Sample 
      
  Unweighted 2220 5053 
    
  Weighted 30276510 68986610 
    
Gender       
     Male 25.48 74.52 0.62 (0.56, 0.69) 0.64 (0.57, 0.73) 
     Female 35.56 64.44 1.00 
 
1.00 
 
Age    
 
 
 
     20-29 46.90 53.10 3.54 (2.98, 4.21) 3.69 (2.98, 4.56) 
     30-39 32.41 67.59 1.92 (1.61, 2.30) 1.85 (1.53, 2.24) 
     40-49 25.47 74.53 1.37 (1.15, 1.63) 1.30 (1.10, 1.54) 
     50-59 19.96 80.04 1.00 
 
1.00 
 
Race/ethnicity    
 
 
 
Non-Hispanic White 29.76 70.24 1.00 
 
1.00 
 
Non-Hispanic Black 35.09 64.91 1.28 (1.10, 1.48) 1.22 (1.03, 1.43) 
Hispanic 29.09 70.91 0.97 (0.82, 1.14) 1.11 (0.92, 1.35) 
Other 38.22 61.78 1.46 (1.15, 1.86) 1.40 (1.06, 1.83) 
Marital status    
 
 
 
Never married 41.38 58.62 1.82 (1.58, 2.11) 1.25 (1.04, 1.50) 
Married 27.90 72.10 1.00 
 
1.00 
 
Previously married 27.36 72.64 0.97 (0.80, 1.18) 1.08 (0.87, 1.36) 
Living with partner 32.24 67.76 1.23 (0.99, 1.52) 1.02 (0.79, 1.31) 
Country of birth    
 
 
 
US 30.77 69.23 1.00 
 
1.00 
 
Mexico 21.37 78.63 0.61 (0.48, 0.78) 0.73 (0.53, 1.02) 
Abroad 32.12 67.88 1.07 (0.85, 1.34) 1.03 (0.80, 1.32) 
Age at first intercourse    
 
 
 
     Less than 18 years old 31.28 68.72 1.09 (0.95, 1.26) 1.06 (0.90, 1.24) 
     >=18 years old 29.40 70.60 1.00 
 
1.00 
 
Education    
 
 
 
Less than high school 22.63 77.37 0.54 (0.46, 0.65) 0.51 (0.41, 0.64) 
Completed high 
school 
23.75 76.25 0.58 (0.50, 0.67) 0.56 (0.47, 0.66) 
Some college or 
beyond 
34.98 65.02 1.00 
 
1.00 
 
Household size    
 
 
 
1-3 people 29.31 70.69 1.00 
 1.00  
4-6 people 32.61 67.39 1.17 (1.02, 1.34) 1.24 (1.08, 1.44) 
7 or more people 30.77 69.23 1.07 (0.76, 1.51) 1.27 (0.82, 1.95) 
Income    
 
 
 
   Less than $20,000 31.40 68.60 0.95 (0.79, 1.14) 0.93 (0.76, 1.13) 
   $20,000 or more 30.36 69.64 1.00  1.00  
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Table 4. Factors associated with receipt of hepatitis B vaccination among adults:  
NHANES 1999-2006 (continued) 
  Vaccinated Unvaccinated Odds Ratios 
  % % Crude (95% CI) Adjusted (95% CI) 
Variables       
Current health insurance  
coverage 
   
 
 
 
     Yes 31.17 68.83 1.18 (1.01, 1.37) 1.20 (0.99, 1.45) 
     No 27.75 72.25 1.00 
 
 
 
Source of usual care    
 
 
 
     Yes 31.42 68.58 1.32 (1.11, 1.57) 1.35 (1.11, 1.64) 
     No 25.78 74.22 1.00 
 
1.00 
 
Health status    
 
 
 
     Excellent 32.28 67.72 1.16 (1.01, 1.33) 1.03 (0.88, 1.20) 
     Very good 31.85 68.15 1.13 (1.00,1.29) 1.05 (0.91, 1.20) 
     Good 29.19 70.81 1.00 
 
1.00 
 
     Fair 28.09 71.91 0.95 (0.79, 1.13) 1.11 (0.91, 1.34) 
     Poor 21.87 78.13 0.68 (0.43, 1.08) 0.88 (0.55, 1.42) 
Cigarette smoker    
 
 
 
     Smoker 30.22 69.78 0.98 (0.85, 1.14) 1.06 (0.90, 1.25) 
     Non-smoker 30.62 69.38 1.00 
 
1.00 
 
History of alcohol abuse    
 
 
 
     Yes 25.40 74.60 0.74 (0.62, 0.88) 0.96 (0.81, 1.15) 
     No 31.52 68.48 1.00 
 
1.00 
 
Received at least 1 dose  
Hepatitis B vaccine 
   
 
 
 
     High risk 32.43 67.57 1.11 (0.93, 1.32) 1.10 (0.91, 1.34) 
     Low risk 30.16 69.84 1.00 
 
1.00 
 
 
When comparing the self reported vaccination status with serologic status, almost half of 
the adults who reported receiving all three doses of the vaccine tested negative for immunity.  
About 4.5% of adults who reported receiving no doses were seropositive (Table 5). 
Table 5. Distribution of participants based on their self report vaccination status and 
serostatus 
  Self reported status 
Serostatus All 3 doses At least 1 dose No doses 
 % % % 
Vaccinated 46.87 23.07 4.51 
Unvaccinated 48.98 73.41 91.99 
History of Hepatitis B infection 4.16 3.51 3.50 
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Figure 1 shows the trend in prevalence of Hepatitis B vaccination between 1999 and 
2006.  For all adults the prevalence increased from 23.4% to 39.1%.  Compared to adults in 
1999-2000, adults were twice as likely to report vaccination in 2005-2006 (OR=2.1 95% CI 
[1.77, 2.49]). 
Figure 1. Trends in self-reported hepatitis B vaccination among adults:  
NHANES 1999-2006 
20
25
30
35
40
45
1999-2000 2001-2002 2003-2004 2005-2006
Pe
rc
en
ta
ge
Year
high risk low risk all adults
 
 
DISCUSSION 
NHANES is the only population based survey that collects data from a nationally 
representative sample and allows estimates of the prevalence of health status and behaviors.  
About 44% (7273 of 16419) of the survey participants between age 20 and 59 identified in this 
study represented approximately one third of the US population.   
All Adults 
The National Health Interview Survey (NHIS) of 2004 reported that only 34.6% of adults 
aged 18 to 49 years had received hepatitis B vaccination.7  In our study, 30.5% of adults aged 20 
to 59 from 1999-2006 reported receiving the hepatitis B vaccine.  Among 20 to 49 year olds 
33.6% reported receiving the hepatitis B vaccination.  It is important to note that the vaccination 
rate increased by almost 15 percentage points between 1999-2000 and 2005-2006.  The highest 
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vaccination rate was reported among 20-29 year olds and is consistent with previous studies that 
provided national estimates.7  This high rate of self-report among 20-29 year olds is most 
commonly attributed to successful childhood and adolescent vaccination from ACIP 
recommendations of 1995.7,24 Even before those recommendations were implemented, some 
states already had laws mandating childhood immunization of hepatitis B before enrolling in 
elementary or middle school.24   As time goes on, it is likely that this cohort effect will continue 
to trend vaccination rates upward for adults.   
In this study, we found that Non-Hispanic blacks and other minorities were more likely to 
be vaccinated than Non-Hispanic whites and Hispanics. NHIS of 2004 also found higher 
reported vaccination rates among non-Hispanics and other minorities.7 While studies have shown 
higher odds of hepatitis B vaccination among minorities, they were not statistically 
significant.7,24,26  Generally, health disparities exist among adults in immunization especially for 
pneumococcal and influenza vaccines.27,28  Even studies with targeted populations of high risk 
young adults minorities found no significant difference in hepatitis B immunization rates when 
compared to other ethnic groups.24,29  
Other social demographics that affected vaccination status were marital status, household 
size, education, insurance coverage, and having a source of usual care.  Studies have shown 
statistically insignificant odds of married and previously married individuals less likely to be 
vaccinated when compared to those who had never been married.7,24,26  
For adults, person-to-person transmission of HBV can occur in settings involving 
nonsexual interpersonal contact over an extended period of time. Risk usually increases with 
household size. In our study, adults who lived with 4 or more people were more likely to be 
vaccinated.  Although this was not significant for household sizes of 7 or more people, being 
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vaccinated for hepatitis B will decrease this group’s likelihood of HBV infection in the future.  
Lower odds of vaccination were found with education of high school or less and lack of health 
insurance coverage and a source of usual care.  These findings were consistent with other 
studies.24-26 Since these individuals are at higher risk of infection, efforts should be initiated to 
improve vaccination rates.   
High-risk adults 
In this study we estimated that almost 15 million adults were at risk of HBV.  Of the high 
risk population only 32% were reported vaccinated.  This percentage is comparable to other 
recent national studies on hepatitis B vaccination among high risk adults.24 In our study the 
report rate increased from 29.2% in 1999-2000 to 41.8% in 2005-2006.  However, being high 
risk was not associated with higher odds of vaccination.  Although acute HBV infection has 
decreased substantially among adults, approximately 95% of the cases of acute HBV cases in 
2005 were among adults.2 Our findings imply that high risk adults remain under-immunized.  
Several city and state interventions have shown success with increases in immunization, 
particularly with the first dose.7,9,30-31  However, funding for maintaining such programs is 
limited and these adults remain at risk for infection.  Unlike national vaccination programs for 
children, there is no similar infrastructure for vaccine administrant to adults.  Numerous barriers 
to vaccination have been identified including cost, time constraints of providers, lack of 
awareness, reluctance to discuss risk behaviors, and non-completion of the three doses.  Adults at 
increased risk also have missed opportunities to receive hepatitis B vaccination with up to a 60% 
rate of lost opportunities.7, 30-31  
Methods used that have shown increased in adult vaccination coverage include reminders 
to health care providers, comprehensive health centers for high risk adults, and patient reminder 
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systems.7 Insufficient evidence is available regarding the effectiveness of in-clinic patient 
education, providing family or patient incentives, or the implementation of state and federal 
laws.31   In 2005, the ACIP recommended strategies to improve vaccination for adults at risk for 
hepatitis B, by increasing access at facilities that have a high proportion of persons more likely to 
be at risk.9  These sites include STD/HIV testing and treatment facilities, correctional facilities, 
and drug-abuse treatment facilities.  
Vaccination serostatus 
The 3-dose hepatitis B vaccine series produces a protective antibody response in 
approximately 30%-55% of healthy adults less than 40 years old after the first dose, 75% after 
the second dose, and greater than 90% after the third dose.9 For adults over the age of 40 
protective antibody response declines below 90% and is only 75% for adults over 60 years old.9 
Our study found that less than 50% of adults who reported receiving all three doses were 
seropositive for vaccination.  Of those who reported receiving at least one dose, 27% already 
showed full protection from HBV.  Among adults who received no doses of the vaccine, 4.5% 
had a seropositive vaccination status.  About 3.5% of adults showed immunity due to history of 
HBV infection.   
Many factors contribute to decreased vaccination response or negative serostatus 
including smoking, obesity, genetics, stress, immune suppression, and loss of antibodies.9,35-39 
Other behavioral and psychological factors also influence immune functions. Studies have shown 
that non-response accounts for about 10-25% of cases.9  Up to 50% of those vaccinated lose their 
antibodies within a few years. However, undetectable anti-HBs levels do not necessarily indicate 
loss of immunity. If exposed to HBV, the immune memory initiates an anamestic response that 
prevents acute and chronic infection.37 While most studies regarding long term immune response 
22 
 
have examined children and adolescents, a few studies have followed the immunologic memory 
in adults who had lost protective antibodies after vaccination.  One study found that participants 
who lost their anti-HBs still had immunologic memory that was able to trigger anti-HBs 
production when revaccinated.37  Other studies suggest that immunologic memory in healthy 
individuals last 5-12 years.35-39  This is also shown in studies that followed high-risk vaccinees.36  
Another factor that affects seropositivity rate is knowledge of vaccination status. In the 
United States, research on the validity of self-reported vaccination status is primarily limited to 
elderly adults or the pneumococcal and influenza vaccines. A study conducted among high risk 
adults in Australia found that 52.2% of those who believed they were protected were not 
immune.32 Previous studies on self-reports of HBV exposure and vaccination among high risk 
adults have found that results were specific, but not sensitive.33 One study in Switzerland found 
that knowledge of HBV vaccination status was associated with gender, language and dietary 
attitudes.34  Researchers and health care providers should be cautious in using such self-reports.  
However, it is also important to properly document when patients receive an immunization and 
to test serostatus after the series completion so they do not receive unnecessary boosters.35-37,39  
The analysis of self-report and serostatus for this data are unpublished at this time. 
Limitations 
Although we had a large sample size, our population was limited to adults aged 20-59 
who provided responses to sensitive questions regarding sexual practices, illegal drug use, also 
provided laboratory examination data for HBV, HCV, and HIV.  Secondly, our study did not 
include estimates on other high risk participants such as people receiving hemodialysis and 
health care workers.  NHANES data are representative of the civilian non-institutionalized US 
population. As a result, populations with higher risk of infection are excluded including 
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incarcerated persons, homeless, military service members, and residents in long-term care 
facilities.  
 Underreporting and recall bias are concern for this study as well.  NHANES uses audio 
computer assisted personal self interview (ACASI) and computer assisted personal interview 
(CAPI) questionnaire.  However, it has been noted that response rates are lower in areas such as 
sexual behaviors and illegal drug use.  There is a possibility that high-risk populations were 
underestimated due to the lower response rates to sensitive questions.  The potential of 
underestimating high risk adults supports the conclusion that a substantial proportion of the US 
population is at risk of HBV. 
 Although the question regarding hepatitis B vaccination status provided a description of 
the vaccine and its recommendations, it is possible that respondents confused their vaccination 
status with others collected in the survey including Hepatitis A, pneumococcal, and influenza.  
However, since these vaccinations are administered to different risk groups, it is unlikely to 
occur.  
CONCLUSIONS 
 Despite these limitations, few studies have examined national estimates of hepatitis B 
vaccination among the general US population.  Although, hepatitis B vaccination rates are rising, 
only 32% of high risk adults are vaccinated.  The rise in vaccination rates in young adults is 
mostly related to childhood immunization strategies and not strategies aimed at adults.  Older 
males, those with less than high school education, without health insurance coverage and a 
source of usual care were least likely to be vaccinated.  More targeted interventions are needed to 
educate and vaccinate the adult population and to create a means for identifying those at risk and 
those already vaccinated.  Interventions should also be implemented to improve adult awareness 
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about vaccinations that may have already received.  Further research will also provide insight 
into social and demographic factors that may affect non-response and loss of antibodies.  Similar 
to programs for children and adolescents, national immunization programs should be 
implemented to target immunization of adults at higher risk of HBV. 
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